Hypomania

First-Ever Psilocybin Clinical Trial for Treatment of Bipolar II Depression Conducted at Sheppard Pratt Reveals Promising Results

Retrieved on: 
Wednesday, December 6, 2023
Psilocybin, Hypomania, Depression, Safety, Research, Argyreia nervosa, Therapy, Treatment, Post-traumatic stress disorder, Ageing, Bipolar II disorder, Clinical trial, Bipolar I disorder, Psychotherapy, Patient, Tic disorder, Psychopharmacology, Psychiatry, Suicide, Trial of the century, JAMA Psychiatry, Mania, Hearing, Psychosis, Pharmaceutical industry

BALTIMORE, Dec. 6, 2023 /PRNewswire/ -- JAMA Psychiatry recently published a first-of-its-kind clinical trial conducted at Sheppard Pratt studying the efficacy and safety of a single dose of synthetic psilocybin accompanied by psychotherapy in treating individuals with treatment-resistant bipolar type II disorder (bipolar II).

Key Points: 
  • BALTIMORE, Dec. 6, 2023 /PRNewswire/ -- JAMA Psychiatry recently published a first-of-its-kind clinical trial conducted at Sheppard Pratt studying the efficacy and safety of a single dose of synthetic psilocybin accompanied by psychotherapy in treating individuals with treatment-resistant bipolar type II disorder (bipolar II).
  • The study revealed promising results with 80% of participants meeting remission criteria 12 weeks after treatment.
  • The results of this study suggest the efficacy and safety of psilocybin in treatment of bipolar II depression, but cannot be extrapolated to the study of psilocybin to treat bipolar I disorder.
  • Sheppard Pratt's Center of Excellence for Psilocybin Research and Treatment is currently conducting clinical trials on psilocybin with psychotherapy for the treatment of anorexia, treatment-resistant depression and chronic suicidal ideation.

World First: New Model And Treatment For Mood Disorders Has Very High Success Rate

Retrieved on: 
Thursday, October 20, 2022
Quality of life, World Psychiatric Association, Bipolar disorder, Agitation, Bipolar, Combined, Patient, Degenerative disease, Depression, Transcranial magnetic stimulation, II, Precision medicine, Hypomania, Thought disorder, Cancer, Treatment, WHO, World Health Organization, Disability, Epilepsy, Depression of Alzheimer disease, Lists of diseases, Alzheimer's disease, Congress, Repetition, BSD, Grammatical mood, Psychiatry, Pharmaceutical industry

LONDON, Oct. 20, 2022 /PRNewswire/ -- A world's first model for mood disorders involving precision medicine and mitochondrial treatment with High Dose Levothyroxine and rTMS (patent application pending), was published by The London Psychiatry Centre .

Key Points: 
  • LONDON, Oct. 20, 2022 /PRNewswire/ -- A world's first model for mood disorders involving precision medicine and mitochondrial treatment with High Dose Levothyroxine and rTMS (patent application pending), was published by The London Psychiatry Centre .
  • This group deteriorates with antidepressants and subthreshold symptoms do not recover with the standardcombination of Quetiapine and mood stabilisers .
  • Dr Andy Zamar, the inventor of the protocol, and his team will be presenting the model and treatment outcomes at the World Psychiatric Association 2022 congress: New Horizons in Psychiatric Practice (10-12 November, Malta).
  • It is also the first in the world to successfully apply precision medicine in psychiatry.

World First: New Model And Treatment For Mood Disorders Has Very High Success Rate

Retrieved on: 
Thursday, October 20, 2022
Quality of life, World Psychiatric Association, Bipolar disorder, Agitation, Bipolar, Combined, Patient, Degenerative disease, Depression, Transcranial magnetic stimulation, II, Precision medicine, Hypomania, Thought disorder, Cancer, Treatment, WHO, World Health Organization, Disability, Epilepsy, Depression of Alzheimer disease, Lists of diseases, Alzheimer's disease, Congress, Repetition, BSD, Grammatical mood, Psychiatry, Pharmaceutical industry

LONDON, Oct. 20, 2022 /PRNewswire/ -- A world's first model for mood disorders involving precision medicine and mitochondrial treatment with High Dose Levothyroxine and rTMS (patent application pending), was published by The London Psychiatry Centre .

Key Points: 
  • LONDON, Oct. 20, 2022 /PRNewswire/ -- A world's first model for mood disorders involving precision medicine and mitochondrial treatment with High Dose Levothyroxine and rTMS (patent application pending), was published by The London Psychiatry Centre .
  • This group deteriorates with antidepressants and subthreshold symptoms do not recover with the standardcombination of Quetiapine and mood stabilisers .
  • Dr Andy Zamar, the inventor of the protocol, and his team will be presenting the model and treatment outcomes at the World Psychiatric Association 2022 congress: New Horizons in Psychiatric Practice (10-12 November, Malta).
  • It is also the first in the world to successfully apply precision medicine in psychiatry.

Digital Health Platform Reduces Bipolar Disorder Symptoms in More Than Half of Users

Retrieved on: 
Wednesday, September 7, 2022
Chronic pain, AUC, UCL, Juli, CEO, University College London, Hospital, Receiver operating characteristic, Caregiver, Research, Comorbidity, Migraine, Air pollution, Altmann, Bipolar disorder, Doctor of Philosophy, Time, Canadian International Council, Associate, Behavior, Psychiatry, Mania, Manic, Randomized controlled trial, Suicide, Asthma, Grammatical mood, ASMR, ASRM, Depression, Hypomania, Patient, Prevalence, Hypertension, Population, Weather, Patient Health Questionnaire, Sleep hygiene, Health, Environment, Lithium, Medical device, Poultry, Pharmaceutical industry, Risk management, ROC, MD

BOSTON, Sept. 7, 2022 /PRNewswire/ -- juli, the AI-powered chronic condition platform, released the results of a first-of-its-kind analysis demonstrating a 55 percent reduction in the number of people with bipolar disorder who experience symptoms of mania after only eight weeks using the juli app.

Key Points: 
  • Bipolar disorder is a lifelong, recurrent, episodic illness with high rates of hospitalization, suicide and comorbidity.
  • As of July 2022, 2,987 people with bipolar disorder had downloaded the juli app.
  • Of those, 77% (2,300) confirmed that they had been diagnosed with bipolar disorder by a psychiatrist.
  • More than half indicated they had experienced bipolar disorder for more than five years and 65 percent were seeing a physician regularly.

Intra-Cellular Therapies Announces Investor Webcast and Presentations on Lumateperone Programs at the Upcoming American Psychiatric Association (APA) Annual Meeting

Retrieved on: 
Thursday, April 22, 2021
Psychiatric diagnosis, Bipolar disorder, Mood disorders, Psychiatry, Abnormal psychology, Depression, Mania, Hypomania, Treatment of bipolar disorder, Major depressive disorder, Bipolar II disorder

These episodes tend to last longer, recur more often, and are associated with a worse prognosis than the manic/hypomanic episodes.

Key Points: 
  • These episodes tend to last longer, recur more often, and are associated with a worse prognosis than the manic/hypomanic episodes.
  • Bipolar depression remains a significantly underserved medical need, with only a few FDA-approved treatment options available.
  • These treatments are commonly associated with tolerability issues.\nCAPLYTA\xc2\xae (lumateperone) is under investigation for the treatment of bipolar disorder.
  • The safety and efficacy for this use has not been established.\nCAPLYTA is indicated for the treatment of schizophrenia in adults.

Global Major Depressive Disorder (MDD) Drug Market Report 2021: Key Players Will Struggle to Maintain Competitiveness - Better Efficacy and Rapid Onset of Action Are the Most Pressing Unmet Needs

Retrieved on: 
Wednesday, April 21, 2021
Psychiatry, Abnormal psychology, Psychiatric diagnosis, Psychology, Psychopathology, Mood disorders, Schizophrenia, Schizoaffective disorder, Schizophreniform disorder, Hypomania, Psychosis, Mania

MDD is only diagnosed if an MDE is not better explained by a psychotic disorder such as schizophrenia, schizoaffective disorder, schizophreniform disorder, delusional disorder, or other psychotic disorder, and if there is no history of hypomania or mania.

Key Points: 
  • MDD is only diagnosed if an MDE is not better explained by a psychotic disorder such as schizophrenia, schizoaffective disorder, schizophreniform disorder, delusional disorder, or other psychotic disorder, and if there is no history of hypomania or mania.
  • The most promising candidates in Phase III development are profiled.\nAnalysis of the current and future market competition in the global Major Depressive Disorder therapeutics market.
  • Insightful review of the key industry drivers, restraints and challenges.
  • Each trend is independently researched to provide qualitative analysis of its implications.\n1.5 What Do Physicians Think?\n'

Global Major Depressive Disorder (MDD) Drug Forecast and Market Analysis, 2019-2020 & 2021-2029: Epidemiology, Etiology, Pathophysiology, Symptoms, Diagnosis, and Disease Management - ResearchAndMarkets.com

Retrieved on: 
Thursday, April 15, 2021
Health, Pharmaceutical, Psychiatry, Psychiatric diagnosis, Abnormal psychology, Mood disorders, Psychology, Schizophrenia, Bipolar disorder, Schizoaffective disorder, Hypomania, Mania, Major depressive disorder, Antidepressant

MDD is only diagnosed if an MDE is not better explained by a psychotic disorder such as schizophrenia, schizoaffective disorder, schizophreniform disorder, delusional disorder, or other psychotic disorder, and if there is no history of hypomania or mania.

Key Points: 
  • MDD is only diagnosed if an MDE is not better explained by a psychotic disorder such as schizophrenia, schizoaffective disorder, schizophreniform disorder, delusional disorder, or other psychotic disorder, and if there is no history of hypomania or mania.
  • The term unipolar depressive disorder is often used to distinguish MDD from depressive episodes that occur in conjunction with manic episodes, known as bipolar disorder.\nThe products in the MDD market generally fall into four main categories: SSRIs, SNRIs, other types of antidepressants, and adjunctive therapies.
  • The most promising candidates in Phase III development are profiled.\nAnalysis of the current and future market competition in the global Major Depressive Disorder therapeutics market.
  • Each trend is independently researched to provide qualitative analysis of its implications.\n1.5 What Do Physicians Think?\n'

Intra-Cellular Therapies Applies for FDA Approval of CAPLYTA® (lumateperone) for the Treatment of Bipolar Depression

Retrieved on: 
Monday, February 22, 2021
Psychiatric diagnosis, Psychiatry, Mood disorders, Abnormal psychology, Bipolar disorder, Depression, Bipolar spectrum, Bipolar II disorder, Bipolar I disorder, Hypomania, Major depressive disorder, Mania

We believe CAPLYTA has the potential to be an important option for patients in the treatment of bipolar depression.

Key Points: 
  • We believe CAPLYTA has the potential to be an important option for patients in the treatment of bipolar depression.
  • We look forward to bringing CAPLYTA to market, if approved, for the treatment of bipolar depression.
  • Bipolar I and Bipolar II disorder are serious, highly prevalent psychiatric conditions affecting approximately 11 million adults in the U.S.
  • These disorders are characterized by recurrent episodes of mania or hypomania interspersed with episodes of major depression known as Bipolar depression.